Align Technology, Inc. (NASDAQ:ALGN)‘s stock had its “buy” rating reissued by Stifel Nicolaus in a research note issued on Monday. They presently have a $205.00 price target on the medical equipment provider’s stock. Stifel Nicolaus’ price target indicates a potential upside of 18.07% from the stock’s previous close.

Several other brokerages have also weighed in on ALGN. Leerink Swann reissued an “outperform” rating and set a $199.00 price objective (up from $194.00) on shares of Align Technology in a report on Friday, July 28th. Bank of America Corporation raised Align Technology from a “neutral” rating to a “buy” rating and increased their price objective for the company from $175.00 to $193.00 in a report on Friday, July 28th. Piper Jaffray Companies reissued a “buy” rating and set a $176.00 price objective on shares of Align Technology in a report on Friday, July 28th. Morgan Stanley reissued an “overweight” rating and set a $182.00 price objective (up from $175.00) on shares of Align Technology in a report on Monday, July 17th. Finally, Credit Suisse Group reissued an “outperform” rating and set a $170.00 price objective (up from $140.00) on shares of Align Technology in a report on Thursday, July 13th. Ten equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $174.40.

Align Technology (NASDAQ ALGN) opened at 173.62 on Monday. Align Technology has a 52 week low of $83.27 and a 52 week high of $176.84. The stock’s 50 day moving average price is $155.86 and its 200 day moving average price is $126.81. The company has a market capitalization of $13.92 billion, a P/E ratio of 59.46 and a beta of 1.55.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.12. Align Technology had a return on equity of 23.87% and a net margin of 19.18%. The business had revenue of $356.50 million during the quarter, compared to analyst estimates of $343.43 million. During the same period in the prior year, the company earned $0.62 earnings per share. Align Technology’s revenue was up 32.3% compared to the same quarter last year. Analysts anticipate that Align Technology will post $3.40 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Align Technology, Inc. (NASDAQ:ALGN) Receives Buy Rating from Stifel Nicolaus” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/09/align-technology-inc-nasdaqalgn-receives-buy-rating-from-stifel-nicolaus.html.

In other news, Director Joseph Lacob sold 50,000 shares of the firm’s stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $144.98, for a total value of $7,249,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Sreelakshmi Kolli sold 1,000 shares of the firm’s stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $144.00, for a total value of $144,000.00. Following the completion of the transaction, the vice president now directly owns 23,785 shares of the company’s stock, valued at $3,425,040. The disclosure for this sale can be found here. Insiders sold 54,874 shares of company stock valued at $7,950,701 over the last ninety days. Corporate insiders own 2.00% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. CENTRAL TRUST Co raised its position in Align Technology by 128.5% in the second quarter. CENTRAL TRUST Co now owns 697 shares of the medical equipment provider’s stock worth $105,000 after buying an additional 392 shares during the last quarter. Van ECK Associates Corp raised its position in Align Technology by 6.9% in the first quarter. Van ECK Associates Corp now owns 1,057 shares of the medical equipment provider’s stock worth $121,000 after buying an additional 68 shares during the last quarter. Trust Co. of Vermont raised its position in Align Technology by 15.4% in the second quarter. Trust Co. of Vermont now owns 1,010 shares of the medical equipment provider’s stock worth $152,000 after buying an additional 135 shares during the last quarter. FNY Partners Fund LP bought a new position in Align Technology during the first quarter worth approximately $160,000. Finally, Livforsakringsbolaget Skandia Omsesidigt bought a new position in Align Technology during the first quarter worth approximately $161,000. 87.13% of the stock is owned by hedge funds and other institutional investors.

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Analyst Recommendations for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.